The lawsuit said that the use of Imfinzi to treat lung and
bladder cancer infringes several Opdivo patents.
Representatives for United Kingdom-based AstraZeneca did not
immediately respond to a request for comment on the lawsuit. A representative
for Bristol-Myers declined to comment.
New York-based Bristol-Myers earned over $7.5 billion from
worldwide sales of Opdivo last year, according to a filing with the U.S.
Securities and Exchange Commission. AstraZeneca's Imfinzi earned the company
over $2.4 billion last year, according to a company report.
Bristol-Myers' lawsuit asked the Delaware court for an
undisclosed amount of monetary damages.
Bristol-Myers' immunotherapy patents relate to a monoclonal
antibody used to destroy cancer cells. Its Opdivo drug is used to treat several
types of cancer, including lung cancer, bladder cancer, melanoma and Hodgkin
lymphoma.
A Bristol-Myers subsidiary previously won $1.2 billion from
a Gilead Sciences unit whose lymphoma immunotherapy drug, Yescarta, was found
to infringe one of its patents. A U.S. appeals court threw out that award last
year. – Reuters
.jpeg)
0 comments:
Post a Comment